Antisense & RNAi Therapeutics Market Valuation Expected To Reach $3.11 Billion By 2029, Growing At A Rate Of 12.8%
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Antisense & RNAi Therapeutics Market Growth Performance Trended Historically, And What Lies Ahead?
The market size of antisense and RNAi therapeutics has experienced a swift upsurge in recent times, with projections showing an increase from $1.75 billion in 2024 to $1.93 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.2%. This augmentation during the historical period can be ascribed to an upswing in funding, technological advancements, and an increase in health care spending, alongside a fast-paced growth in the aged population and the economic expansion in budding markets.
In the coming years, the antisense & RNAi therapeutics market is projected to experience substantial growth, expanding to $3.11 billion in 2029 at a Compound Annual Growth Rate (CAGR) of 12.8%. The projected growth during this period can be attributed to better healthcare access, the increasing rate of cancer, and a boosted demand for antisense and RNAi therapeutics, driven by COVID-19. The forecast period will see major trends such as concentrated research and development efforts for RNA therapeutics towards orphan diseases, the use of nanoparticles, the creation of improved and new antisense and RNAi therapeutics, and company collaborations for product innovation and revenue growth.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp
Which Factors and External Forces Are Driving Demand in the Antisense & RNAi Therapeutics Market?
The antisense & RNAi therapeutics market is anticipated to benefit from the growing occurrence of coronary artery diseases, neurodegenerative disorders, and infections. Approaches such as RNA interference and antisense oligonucleotides, which suppress gene expression, are utilized to treat a variety of neurodegenerative diseases by repairing defective genes. For example, a report from the American Heart Association, a US-based organization, stated in January 2024 that the age-adjusted death rate from heart-related illnesses had risen to 233.3 per 100,000, indicating a 4.0% increase from the preceding year. As a result, the rising incidences of numerous neurodegenerative disorders and infectious ailments are anticipated to stimulate the antisense & RNAi therapeutics market’s expansion.
Which Segments in the Antisense & RNAi Therapeutics Offer the Most Growth?
The antisense & rnai therapeutics market covered in this report is segmented –
1) By Technology: RNA Interference, Antisense RNA
2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
Subsegments:
1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics
2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=3389&type=smp
What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Antisense & RNAi Therapeutics Market?# Market?
North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Which Cutting-Edge Market Trends Are Expected to Drive theAntisense & RNAi Therapeutics Market’s Growth?
Key players in the antisense & RNAi therapeutics market are embracing strategic actions like partnerships and collaborations to retain their competitiveness in the ever-tightening industry. The concept of strategic collaboration refers to several businesses pooling resources together to achieve shared goals. For instance, Orbit Discovery Limited, an American company that provides peptide discovery services, formed a partnership with SanegeneBio Inc., a UK-based firm that develops novel RNAi-based medicines, in January 2023. Their goal was to identify tissue-specific delivery of RNA therapeutics for efficient gene knockdown and consequently create a series of advanced RNAi therapeutics. The agreement included hit identification and cellular internalization studies, with Sanegene earning the option to advance the screened hits using Orbit’s distinctive technology for quick peptide lead discovery. Orbit Discovery’s exclusive peptide display technology allows the screening of enormous peptide libraries, thus facilitating faster discovery of suitable peptide leads through affinity and functionality screens.
View the full report here:
What Are the Key Elements That Define the Antisense & RNAi Therapeutics Market?
Antisense therapy refers to the selective, sequence-specific suppression of gene expression by single-stranded DNA oligonucleotides. Contrarily, RNA interference (RNAi) is activated by double-stranded RNA (dsRNA) and results in the sequence-specific mRNA degradation of single-stranded target RNAs.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3389
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
